FEASIBILITY OF POSTMASTECTOMY RADIATION-THERAPY AFTER TRAM FLAP BREAST RECONSTRUCTION

Citation
Kk. Hunt et al., FEASIBILITY OF POSTMASTECTOMY RADIATION-THERAPY AFTER TRAM FLAP BREAST RECONSTRUCTION, Annals of surgical oncology, 4(5), 1997, pp. 377-384
Citations number
26
Categorie Soggetti
Surgery,Oncology
Journal title
ISSN journal
10689265
Volume
4
Issue
5
Year of publication
1997
Pages
377 - 384
Database
ISI
SICI code
1068-9265(1997)4:5<377:FOPRAT>2.0.ZU;2-X
Abstract
Background: Postoperative radiotherapy (PORT) has been shown to decrea se locoregional failure rates in high-risk breast cancer patients foll owing modified radical mastectomy. However, there had not been a study evaluating the effect of PORT in patients after transverse rectus abd ominis myocutaneous (TRAM) flap breast reconstruction. Therefore, we e valuated flap viability, cosmetic results, and locoregional recurrence in patients who underwent TRAM flap reconstruction and PORT. Methods: The charts of patients who had undergone modified radical mastectomy with TRAM flap reconstruction and PORT at our institution were reviewe d, Patients were examined in the clinic and interviewed by telephone t o evaluate their perceptions of the cosmetic result. Results: PORT was delivered to 19 patients with TRAM flaps (3 pedicled and 16 free flap s) between 1988 and 1994, There were no TRAM flap losses as a result o f either surgical or radiotherapy complications. Two patients develope d fat necrosis, one with a pedicled and one with a free TRAM flap. Pat ients with pedicled TRAM flaps noted more volume loss in the breast af ter radiation therapy. Eighty-four percent of patients felt their over all cosmetic result was excellent or good; only one patient reported a poor cosmetic result. Local control was achieved in three of the four patients who received PORT for local recurrence. There was only one l ocal recurrence among the 14 patients who received PORT because they w ere at high risk of local recurrence. Conclusions: These results sugge st that PORT can be given safely to high-risk patients following TRAM flap breast reconstruction with excellent cosmetic results and good lo coregional control.